Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
16.45
28.6
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Shanghai MicroPort EP Medtech Co Ltd
Research & Development
Shanghai MicroPort EP Medtech Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
S
|
Shanghai MicroPort EP Medtech Co Ltd
SSE:688351
|
Research & Development
-¥85m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
A
|
APT Medical Inc
SSE:688617
|
Research & Development
-¥219.1m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-34%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jiangsu Yuyue Medical Equipment & Supply Co Ltd
SZSE:002223
|
Research & Development
-¥512.2m
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Shenzhen Mindray Bio-Medical Electronics Co Ltd
SZSE:300760
|
Research & Development
-¥3.5B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
J
|
Jafron Biomedical Co Ltd
SZSE:300529
|
Research & Development
-¥243.7m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
|
Shanghai United Imaging Healthcare Co Ltd
SSE:688271
|
Research & Development
-¥1.7B
|
CAGR 3-Years
-32%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Shanghai MicroPort EP Medtech Co Ltd
Glance View
Shanghai MicroPort EP Medtech Co. Ltd. has carved a distinct niche for itself within the rapidly evolving medical device industry, primarily focusing on electrophysiology. This innovative field deals with diagnosing and treating arrhythmias—irregular heartbeats that affect countless individuals globally. MicroPort EP's flagship products include advanced catheter-based systems and cardiac mapping technologies that physicians utilize to pinpoint and correct these heart rhythm disorders. Their solutions are intricately designed to improve the accuracy and effectiveness of ablation procedures, allowing for non-invasive interventions that can significantly enhance patient outcomes. By capitalizing on the increasing prevalence of cardiovascular ailments and the push towards less invasive medical treatments, the company has positioned itself as a pivotal player in the healthcare sector, gaining a competitive edge with its sophisticated R&D capabilities and product innovation. The company's revenue model revolves around the development, manufacturing, and sales of its proprietary electrophysiology devices. By investing heavily in research and development, MicroPort EP continually advances its product offerings, aiming to stay ahead of its competitors and meet the growing demands of healthcare professionals and patients alike. Sales are driven both domestically, within China's burgeoning healthcare market, and internationally, tapping into the global need for cutting-edge cardiac solutions. The integration of technology and healthcare expertise underscores their commitment to quality and innovation, ensuring a sustainable model as they advance in this niche sector. Ultimately, their financial performance reflects a strategic alignment with health trends and technological progress, allowing them to capture value in a market poised for significant growth.
See Also
What is Shanghai MicroPort EP Medtech Co Ltd's Research & Development?
Research & Development
-85m
CNY
Based on the financial report for Dec 31, 2023, Shanghai MicroPort EP Medtech Co Ltd's Research & Development amounts to -85m CNY.
What is Shanghai MicroPort EP Medtech Co Ltd's Research & Development growth rate?
Research & Development CAGR 3Y
-29%
Over the last year, the Research & Development growth was -16%. The average annual Research & Development growth rates for Shanghai MicroPort EP Medtech Co Ltd have been -29% over the past three years .
You don't have any saved screeners yet
